Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. III: pharmacokinetics and targeting characteristics of osteotropic carboxyfluorescein

Jiro Fujisaki, Takehisa Hata, Fumio Shimojo(Mochida Pharmaceutical (Japan)), Toshiya Takahashi(Tohoku University), Yuji Tokunaga(National Institute of Advanced Industrial Science and Technology), Sumihisa Kimura, Taiji Sawamoto(Mochida Pharmaceutical (Japan))
Journal of drug targeting
January 1, 1996
10.3109/10611869609046270
Cited by 17

Related Papers

Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double‐Blind, Randomized, Parallel‐Group Trial
|Arthritis & Rheumatology|2016|119
Psoriasis and Antimicrobial Peptides
|International Journal of Molecular Sciences|2020|114
An In Vitro Test to Screen Skin Sensitizers Using a Stable THP-1–Derived IL-8 Reporter Cell Line, THP-G8
|Toxicological Sciences|2011|93
Cathelicidin promotes inflammation by enabling binding of self-RNA to cell surface scavenger receptors
|Scientific Reports|2018|84
Bone-specific delivery and sustained release of diclofenac, a non-steroidal anti-inflammatory drug, via bisphosphonic prodrug based on the Osteotropic Drug Delivery System (ODDS)
|Journal of Controlled Release|2001|75